Merck (MRK) Profit After Tax Growth (5y) (2014 - 2026)
Merck (MRK) Profit After Tax Growth (5y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.78% |
| Dec 31, 2025 | 25.66% |
| Sep 30, 2025 | 20.01% |
| Jun 30, 2025 | 13.55% |
| Mar 31, 2025 | 9.55% |
| Dec 31, 2024 | 31.83% |
| Sep 30, 2024 | 10.64% |
| Jun 30, 2024 | 15.61% |
| Mar 31, 2024 | 10.31% |
| Dec 31, 2023 | -21.82% |
| Sep 30, 2023 | 19.49% |
| Jun 30, 2023 | -40.54% |
| Mar 31, 2023 | 30.83% |
| Dec 31, 2022 | 37.08% |
| Sep 30, 2022 | 126.79% |
| Jun 30, 2022 | 15.12% |
| Mar 31, 2022 | 22.58% |
| Dec 31, 2021 | 48.42% |
| Sep 30, 2021 | 15.90% |
| Jun 30, 2021 | 5.10% |